Provigil
ApprovedSmall molecule
Mylan Pharmaceuticals IncProvigil is one of 50 small molecule programs targeting Fatigue. It is currently in Approved.
2
Indications
7
Total Trials
0
Active Trials
49
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
101 competitors in Cocaine Dependence
#DrugCompanyPhaseTrials
1Permax
VValeant Pharmaceuticals
Phase 3
Bupropion XL
GSKPhase 3
Celexa
AbbViePhase 2
Ritalin
NovartisPhase 2
Buspar
Bristol-Myers SquibbPhase 2
Tegretol
NovartisPhase 2
Dostinex
PfizerPhase 2
Sabril
LundbeckPhase 2
Antabuse
TevaPhase 2
Lioresal
NovartisPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Fatigue2 trials
Cocaine Dependence1 trial
Concentration1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Provigil. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company